Supplementary Table 1.
Baseline Characteristics of Study Participants
| Variables | Vaccine |
Control |
P |
|---|---|---|---|
| (n = 1133) | (n = 791) | ||
| Patient who received the first dose | … | ||
| Pfizer BNT162b2 mRNA vaccine | 539 (47.6) | … | |
| Moderna 1273 mRNA vaccine | 596 (52.4) | … | |
| Sex | <.0001 | ||
| Male | 1106 (97.6) | 736 (93.1) | |
| Female | 27 (2.4) | 55 (6.9) | |
| Median age, y (IQR) | 68.9 (7.9) | 68.6 (8.7) | .4629 |
| Age group | .0184 | ||
| <50 y | 30 (2.6) | 37 (4.7) | |
| 50–59.9 y | 110 (9.7) | 76 (9.6) | |
| 60–69.9 y | 516 (45.5) | 341 (43.1) | |
| 70–84.9 y | 477 (42.1) | 333 (42.1) | |
| >85 y | 0 (0.0) | 4 (0.5) | |
| White | 755 (66.6) | 479 (60.6) | .0062 |
| Median body mass index (IQR) | 30.2 (5.5) | 30.2 (4.8) | .3851 |
| Current smoker | 227 (20.0) | 180 (22.8) | .1505 |
| Chronic obstructive pulmonary disease | 319 (28.2) | 137 (17.3) | <.0001 |
| Hypertension | 917 (80.9) | 562 (71.1) | <.0001 |
| Kidney transplantation | 223 (19.7) | 117 (14.8) | .0057 |
| Tacrolimus | 917 (80.9) | 454 (57.4) | <.0001 |
| Cyclosporine | 78 (6.9) | 47 (5.9) | .4092 |
| Calcineurin inhibitor–based primary immunosuppression | 1055 (93.1) | 568 (71.8) | <.0001 |
| Mycophenolate | 610 (53.8) | 331 (41.8) | <.0001 |
| Azathioprine | 86 (7.6) | 36 (4.5) | .0071 |
| Antimetabolites | 696 (61.4) | 367 (46.4) | <.0001 |
| Median year from transplantation (IQR) | 5.6 (5.0) | 8.4 (7.5) | <.0001 |
Values are n (%) unless otherwise defined. IQR, interquartile range.